DNA

Stock Performance: Ginkgo Bioworks Holdings, Inc. (DNA) closed at $7.27 with a 1.39% increase, outperforming the S&P 500 and Nasdaq, despite a significant 37.27% loss over the past month.

Earnings Projections: The company is expected to report an EPS of -$1.23 and revenue of $41.26 million, with positive analyst revisions indicating confidence in future performance, reflected in its Zacks Rank of #2 (Buy).

U.S. Stock Futures: U.S. stock futures rose this morning, with Dow futures up approximately 100 points, despite several companies reporting disappointing quarterly financial results leading to significant pre-market declines in their stock prices.

Flywire Corporation and Other Stocks: Flywire Corporation's shares fell 29.2% after reporting losses and sales that missed analyst expectations, while other companies like Liberty Global Ltd., Accel Entertainment, and Grocery Outlet also experienced substantial drops in pre-market trading due to poor earnings reports.

Ginkgo Bioworks Stock Performance: Ginkgo Bioworks (DNA) has experienced a decline of 12.5%, dropping to $9.00 per share, with analysts expressing cautious outlooks and lowering price targets.

Analyst Ratings and Financial Outlook: Despite the stock's downturn, some analysts maintain a Buy rating due to growth potential in tools and AI offerings, although revenue projections for FY25 are below consensus estimates.

Market Overview: U.S. stock futures rose ahead of Nvidia's earnings report, with all four benchmark indices showing gains in premarket trading. The Federal Reserve is expected to maintain interest rates unchanged for the March meeting, while mixed performance was noted in various sectors during the previous session.

Earnings and Economic Insights: Analysts are closely watching Nvidia's earnings for insights on artificial intelligence and chip technology. Additionally, demographic trends may influence inflation and economic growth, prompting investors to adjust their strategies accordingly.

ZoomInfo Technologies Inc. Performance: Shares of ZoomInfo rose 19.6% in pre-market trading after reporting better-than-expected fourth-quarter earnings and issuing optimistic first-quarter revenue guidance.

Market Movements: Several stocks experienced significant changes in pre-market trading, with Enveric Biosciences rising 120.3% due to promising treatment results, while Liberty Global saw a sharp decline of 40.4%.

Analyst Rating: Matt Larew from William Blair has maintained a Sell rating on Ginkgo Bioworks Holdings, with the company's shares closing at $10.29 and an analyst consensus rating of Hold with a $12.00 average price target.

Company Performance: Ginkgo Bioworks has a market cap of $601.2M, a P/E ratio of -0.81, and reported a Q4 EPS of ($2.00), which was below the consensus estimate of ($1.30).

Ginkgo Bioworks Revenue Projections: Ginkgo Bioworks anticipates FY25 Cell Engineering revenue between $110M-$130M, with Biosecurity revenue expected to reach at least $50M, contingent on government funding and program renewals.

Investment Insights: TipRanks offers tools for investors to identify stocks with Strong Buy ratings and optimize their portfolios through its Stock Screener feature.

Pre-Earnings Options Activity: Ginkgo Bioworks (DNA) shows normal pre-earnings options volume with a call to put ratio of 8:5, and the market anticipates a price move of approximately 17.6% following earnings results.

Stock Analysis Tools: TipRanks offers tools for investors to identify strong buy stocks and optimize their portfolios, including a stock screener for analyzing investment opportunities.

Financial Performance: Ginkgo Bioworks reported a Q4 GAAP EPS of -$2.00, missing estimates by $0.50, while revenue reached $43.85 million, up 26.2% year-over-year but also falling short of expectations by $0.58 million.

2025 Revenue Guidance: The company anticipates total revenue between $160-$180 million for 2025, with cell engineering revenue projected at $110-$130 million and biosecurity revenue expected to exceed $50 million, contingent on government funding and program renewals.

Financial Performance Update: Ginkgo Bioworks reported a total revenue of $44 million for Q4 2024, marking a 29% increase in Cell Engineering revenue compared to the previous year. Despite a GAAP net loss of $(108) million, there was significant improvement in cash flow and a reduction in operating expenses.

Restructuring and Future Outlook: The company has completed site consolidation and achieved an annualized cost reduction of $190 million, aiming to reach $250 million by Q3 2025. For 2025, Ginkgo expects total revenue between $160-$180 million, with a focus on expanding its Cell Engineering and Biosecurity sectors.

Integration of Callisto™ System: Volta Labs and Ginkgo Bioworks have integrated the Callisto™ Sample Prep System into Ginkgo's Illumina sequencing workflow, enhancing automation for complex processes like PacBio library prep and size selection.

Advancements in Genomics Applications: The new Double-Sided Size Selection app on Callisto allows labs to efficiently purify DNA fragment sizes for sequencing, showcasing Volta Labs' innovative digital fluidics platform aimed at improving sample preparation consistency and scalability.

International Collaboration: Ginkgo Bioworks has partnered with the European Health and Digital Executive Agency to develop a rapid metagenomic next-generation sequencing (mNGS) solution for identifying respiratory pathogens, supported by up to €24 million in funding from the EU4Health program.

Enhanced Diagnostic Capabilities: The RANGER project aims to create a bedside diagnostic tool that can provide results within 6 hours, improving hospital triage and pandemic preparedness by enabling the identification of both known and novel respiratory pathogens.

Upcoming Presentation: Ginkgo Bioworks Holdings, Inc. will host a presentation and Q&A session on February 25, 2025, to review its business performance for Q4 and the full year of 2024.

Company Overview: Ginkgo Bioworks is a leading platform in cell programming and biosecurity, offering services across various sectors including food, agriculture, pharmaceuticals, and industrial chemicals.

Ginkgo Bioworks 2025 Ferment Series Announcement: Ginkgo Bioworks has announced the 2025 Ferment Series, a series of focused conferences aimed at showcasing advancements in cell engineering and biosecurity, with events scheduled throughout the year in Boston's Seaport District.

Focus Areas and Innovations: Each event will cover specific topics such as AI-driven data generation, biopharma solutions, biosecurity strategies, and automation technologies, featuring industry experts and highlighting Ginkgo's new products and services.

Coherent Corp Financial Results: Coherent Corp's shares surged 15.5% after reporting second-quarter earnings of 95 cents per share, exceeding analyst expectations of 69 cents, along with sales of $1.44 billion, surpassing the $1.37 billion estimate.

Pre-Market Stock Movements: Several stocks experienced significant pre-market trading fluctuations, with SharpLink Gaming gaining 43.5% and Avinger Inc dropping 29.4%, reflecting a mix of positive earnings reports and disappointing guidance across various companies.

New Laboratory Automation System: Ginkgo Bioworks is developing a customizable anaerobic-enabled laboratory automation system for the Great Lakes Bioenergy Research Center (GLBRC) at the University of Wisconsin–Madison, aimed at enhancing biofuel research efficiency by allowing multiple experiments to run simultaneously.

Enhanced Research Capabilities: The new system will provide advanced automation and remote troubleshooting support, enabling GLBRC scientists to focus more on data analysis and innovation rather than routine lab tasks, ultimately advancing sustainable biofuel production.

Ginkgo Bioworks Lobbying Disclosure: Ginkgo Bioworks Inc. disclosed $70,000 in lobbying efforts for Q4 2024, focusing on educating government stakeholders about their capabilities in wastewater surveillance, biomanufacturing, and cell engineering, while supporting relevant appropriations and authorization language.

Insider Trading Activity of DNA Stock: In the past six months, insiders have sold $DNA stock 12 times without any purchases, with 19 institutional investors increasing their holdings and 219 reducing their positions in the latest quarter.

Government Payment to Ginkgo Bioworks: The Department of Health and Human Services made a $54M payment to Ginkgo Bioworks for a Traveler-Based Genomic Surveillance Program, with total awards amounting to $122,757,178 over the past year.

Insider Trading Activity: In the last six months, insiders of Ginkgo Bioworks have sold stock 12 times without any purchases, while institutional investors showed mixed activity, with 19 increasing and 219 decreasing their positions in the most recent quarter.

Event Announcement: Ginkgo Bioworks Holdings, Inc. will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 16, 2025, at 1:30 PM ET.

Webcast Access: The live webcast of the event can be accessed through Ginkgo Bioworks' investor relations website.

NeoGenomics Stock Surge: NeoGenomics shares rose 9.1% to $13.78 following a strategic partnership with Adaptive Biotechnologies to enhance MRD monitoring for blood cancers, despite a previous 29.7% loss over the past month.

Earnings Expectations and Market Position: The company is expected to report quarterly earnings of $0.02 per share, with a positive trend in earnings estimate revisions indicating potential stock price appreciation; it currently holds a Zacks Rank #1 (Strong Buy).